Report
Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Matthew Barcus
  • Robert Driscoll

Weekly Retail Sales Tracker for Hem. Malignancies - Week Ended February 7

Underlyings
Karyopharm Therapeutics

Karyopharm Therapeutics is a clinical-stage pharmaceutical company. The company is focused on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has discovered and is developing small molecule Selective Inhibitors of Nuclear Export (SINE), compounds that inhibit the nuclear export protein (XPO1). The company's SINE compounds were the first oral XPO1 inhibitors in clinical development. The company's focus is on seeking the commercialization of its primary drug candidate, selinexor (KPT-330), as an oral agent in cancer indications with clinical need, initially for hematologic malignancies.

Stemline Therapeutics Inc

Stemline Therapeutics is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The company's product, ELZONRIS? (tagraxofusp-erzs; SL-401) has been approved by the U.S. Food and Drug Administration for the treatment of blastic plasmacytoid dendritic cell neoplasm in adult and pediatric patients two years and older. The company's pipeline of product candidates includes: SL-801 for patients with solid tumors; SL-701, an immunotherapeutic, which has completed a Phase 2 trial in patients with second-line glioblastoma; and SL-901, an oral, small molecule kinase inhibitor, assessed in Phase 1 trial of patients with solid tumors.

Provider
Wedbush
Wedbush

Since our founding in 1955, Wedbush has been a leader in the financial industry providing our clients with a wide range of services; including institutional sales, correspondent clearing services, equity research, corporate and municipal finance, equity market making, fixed income trading, prime brokerage, and wealth management. Headquartered in Los Angeles, with 100 registered offices, the firm focuses on dedicated service, client financial safety, continuity, and advanced technology.

Analysts
Ashiq Mubarack

David Nierengarten

Jeffrey La Rosa

Matthew Barcus

Robert Driscoll

Other Reports on these Companies
Other Reports from Wedbush
David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus
Jay McCanless
Other Reports from these Analysts
David Nierengarten ...
  • Jeffrey La Rosa
  • Matthew Barcus
Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Matthew Barcus
  • Robert Driscoll
Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kambiz Yazdi
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

ResearchPool Subscriptions

Get the most out of your insights

Get in touch